The short answer
When your Chief Technology Officer alerts you that your primary rival filed an inter partes review against your foundational patent, they are announcing an existential assault on your balance sheet[cite: 1]. In the pharmaceutical and biotechnology sectors, intellectual property is not an abstract legal asset. It is the legal monopoly that justifies your research capital, secures your commercial margins, and defends your market capitalization. Dismissing this filing as routine administrative noise is reckless negligence. You must confront the threat with immediate, aggressive institutional mobilization[cite: 1].
Your mandate is to establish total command over the narrative before panic infects your board of directors and institutional investors. You do not downplay the exposure. You name the exact revenue concentration at risk, demonstrating that executive leadership faces reality without blinkers[cite: 1]. You immediately activate your formal corporate defense protocol, allocate substantial litigation capital, and retain premier patent trial litigators who specialize in administrative patent challenges[cite: 1].
You must prove to internal stakeholders and Wall Street analysts that your legal fortress is fully funded and ready for war[cite: 1]. You replace internal anxiety with a structured, disciplined litigation timeline[cite: 1]. You refuse to allow an aggressive competitor to cast doubt on your scientific integrity or your commercial exclusivity, countering their filing with undeniable legal firepower[cite: 1].
Why this question is a trap
This confrontation is a lethal corporate governance trap designed to expose weak executive risk management. An inter partes review at the patent office is a low-cost, high-leverage weapon used by generic manufacturers and predatory competitors to break proprietary drug monopolies before the patent expires. The filing immediately introduces uncertainty regarding your future cash flows. If you respond with flippant dismissals, claiming your patent is unassailable, you look scientifically arrogant and commercially naive to institutional investors who have seen hundreds of valid patents invalidated by administrative boards.
Panicking and suggesting premature settlement talks is an equally disastrous trap. If your immediate reaction is to explore licensing deals or royalty-sharing arrangements with the challenger, you signal to the entire market that your patent claims are legally weak. Every competitor in the sector will file their own challenges, turning a single dispute into a coordinated multi-front assault that bleeds your legal budget and destroys your pricing power.
The unstated agenda of the competitor's executive team is enterprise destabilization. They want to stall your upcoming clinical rollouts, complicate your secondary stock offerings, and scare off potential co-development commercial partners. They time these filings to create maximum friction during quarterly earnings calls or regulatory approval windows. If you show fear, you hand them a public relations victory that depresses your equity multiple for quarters.
You face massive tension between fiscal discipline and legal expenditure. Patent trials are notoriously expensive, often costing tens of millions of dollars. Your structural incentive is to commit capital immediately and decisively. You must demonstrate that management will spend whatever it takes to defend the balance sheet, forcing the competitor to recognize that their challenge will be met with absolute resistance rather than an easy concession[cite: 1].
What most people say
Most chief executives fail this scenario by falling into the trap of false reassurance. A weak chief executive says, "Our scientists spent ten years developing this compound and the patent office granted us broad protection. This filing is just a standard nuisance move by a jealous rival. Do not worry about it, our internal patent lawyers will file a routine response and get it thrown out." This response destroys executive credibility. Internal patent attorneys rarely have the specialized trial firepower needed to defeat an aggressive inter partes review. Minimizing the threat blinds the board to potential revenue loss and leaves the company unprepared when the patent office agrees to institute the review.
Another catastrophic failure is the defeatist, cost-cutting reaction. A panicked leader might say, "We cannot afford to spend twenty million dollars fighting this in court right now when our clinical trials are already consuming all our cash. Let us reach out to their CEO quietly and see if we can settle this through a minor licensing agreement before it becomes public." This response is corporate surrender. Offering a license at the first sign of friction proves your claims cannot withstand scrutiny, inviting further attacks and destroying the enterprise value of your drug pipeline.
Both of these amateur reactions fail because they treat an existential asset challenge as either an irrelevant distraction or an unmanageable crisis. When you fail to allocate capital and activate formal trial defense protocols instantly, you forfeit your monopoly and sacrifice the company's financial future.
What to say instead
"This patent challenge puts seventy percent of our revenue at risk. We are activating our formal legal defense protocol right now. I will allocate ten million dollars to hire top litigators today. We will confirm our lead trial team before Friday afternoon."[cite: 1]
This script works because it executes a flawless transition from hard financial honesty to aggressive capital deployment[cite: 1]. The first sentence names the exact operational stakes[cite: 1]. You state clearly that the challenge puts seventy percent of revenue at risk[cite: 1]. You do not hide behind vague corporate phrases. By stating the true number, you prove to your technical leadership and your board that you grasp the mathematical reality of the threat completely[cite: 1].
The second sentence establishes immediate procedural control[cite: 1]. You announce the activation of your formal legal defense protocol right now[cite: 1]. This demonstrates that your company does not invent ad-hoc solutions during a crisis. You operate from a prepared, institutional playbook designed to protect critical assets under acute pressure[cite: 1].
The third sentence deploys serious balance sheet resources[cite: 1]. You commit to allocating ten million dollars to hire top litigators today[cite: 1]. This moves the response from legal theory to tangible war-chest funding. You signal to your team, the board, and the market that you are backing your scientific integrity with massive capital firepower to secure premier trial talent[cite: 1].
The final sentence establishes an aggressive, non-negotiable operational timeline[cite: 1]. You commit to confirming your lead trial team before Friday afternoon[cite: 1]. You do not allow the decision to linger for weeks in committee reviews. You move with speed, establishing executive command and ensuring that your defense is fully operational before the market opens next week[cite: 1].
The phrase to anchor on
legal defense protocol[cite: 1]
How to deliver it
Your physical delivery must project unyielding resolve, institutional power, and cold discipline. Sit upright with your hands placed firmly on the conference table. Do not slouch, lean back in defeat, or look startled by the news. Your physical presence must communicate that you view this patent challenge as an expected commercial battle that your company is fully equipped to win.
Your vocal pitch must be steady, low, and completely devoid of panic. When you acknowledge that seventy percent of revenue is at risk, speak with clinical, unsentimental gravity[cite: 1]. Drop your pitch sharply on the words "legal defense protocol." This downward inflection reinforces that the corporate machine has pivoted into an established defense posture, shutting down internal panic and speculation.
Maintain direct, unbroken eye contact with your Chief Technology Officer when announcing the ten-million-dollar capital allocation[cite: 1]. Deliver the dollar figure with the natural authority of an executive who commands the balance sheet. Deliver the final sentence regarding the Friday trial team deadline with crisp finality[cite: 1]. You are ending the briefing and initiating immediate execution.
Mistakes that cost you the room
Relying solely on in-house legal counsel for defense strategy. Never attempt to save money by having your internal corporate attorneys handle the patent review trial. In-house counsel excel at portfolio prosecution, not high-stakes courtroom litigation. Hire elite, specialized patent trial lawyers with a proven record of defeating inter partes reviews at the federal level.
Failing to brief the board's lead director immediately. Do not keep the patent challenge a secret from your board while you assemble the defense. Director panic occurs when they read about patent challenges in the financial press before hearing from management. Send a formal executive memo to the board within two hours of learning of the filing, outlining the exact script and capital allocation.
Allowing public relations teams to issue generic statements about innovation. Do not let your communications team post defensive statements claiming your competitor is anti-innovation. Public relations campaigns do not influence administrative patent judges. Keep your public commentary strictly focused on the strength of your issued patents and your confidence in formal legal review.
Practice plan
First, record yourself delivering the script on camera. Watch the playback to ensure your facial expression remains completely steady and determined when you say "seventy percent of our revenue at risk"[cite: 1]. You must train yourself to state immense commercial stakes without showing physical dread.
Second, drill the transition from identifying the risk to deploying the capital. Practice the pivot from "formal legal defense protocol" directly into "allocate ten million dollars to hire top litigators today"[cite: 1]. You must master the delivery of decisive capital commitments under pressure.
Third, practice the anchor phrase. Repeat "legal defense protocol" out loud until it sounds like an impenetrable institutional shield that commands total confidence from investors and directors[cite: 1]. This speaking drill provides communication technique training and does not constitute formal legal, financial, or governance advice.